Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Randomized, Active-Controlled, Double-Masked Study to Evaluate the Safety and Efficacy of TRS01 Eye Drops in the Treatment of Subjects With Active Non-infectious Anterior Uveitis Including Subjects With Uveitic Glaucoma

Next Previous
Trial Profile

A Phase 3 Randomized, Active-Controlled, Double-Masked Study to Evaluate the Safety and Efficacy of TRS01 Eye Drops in the Treatment of Subjects With Active Non-infectious Anterior Uveitis Including Subjects With Uveitic Glaucoma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dazdotuftide (Primary)
  • Indications Anterior uveitis; Glaucoma
  • Focus Registrational; Therapeutic Use
  • Acronyms TRS4Vision
  • Sponsors Tarsier Pharma

Most Recent Events

  • 13 Nov 2023 According to a Tarsier Pharma media release, the company announced the successful outcome of a Type C meeting with the U.S. Food and Drug Administration (FDA) and pleased to have FDA agreement on the primary and key secondary endpoints for the registrational program of TRS01 to reflect TRS01 positive risk/benefit profile for patients with noninfectious uveitis and uveitic glaucoma. The Type C meeting was supported by results from this trial.
  • 23 Aug 2023 Status changed from active, no longer recruiting to completed.
  • 23 Aug 2023 According to a Tarsier Pharma media release, topline data from the TRS4Vision trial will be presented in an oral presentation at the IOIS 2023 Congress.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top